Thrombophilia Risk Assessment

Genetic testing for the following 15 gene mutations:

• Factor V Leiden mutation (F5 G1691A)
• Factor V Cambridge mutation (F5 Arg306Thr)
• Factor V mutation H1299R (R2 haplotype)
• Factor V mutation Y1702C
• Prothrombin (Factor II) mutation G20210A
• Factor XII polymorphism
• Factor XIII mutation/polymorphism
• (commonly tested Val34Leu (V34L))
• β-fibrinogen gene mutation 455 G/A
• PAI-1 (plasminogen activator inhibitor-1) gene mutation (4G/5G)
• MTHFR gene mutation C677T
• MTHFR gene mutation A1298C
• HPA (glycoprotein IIIa/ITGB3) polymorphism
• ACE gene polymorphism (I/D)
• AGT (angiotensinogen) gene mutation
• Apolipoprotein E (APOE) polymorphism
• Apolipoprotein B (APOB) gene mutation R3500Q

Recommendation for when to conduct the test: The test can be performed when planning a pregnancy or at any time during pregnancy, and it is recommended before starting hormonal contraception.

Sample: Blood.

Time for completion from sample receipt in the laboratory: 10–12 business days.